Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

A medical research study for participants who have been diagnosed with a solid tumor (i.e. cancer) and currently, the tumor is unresponsive to approved treatments, approved treatments are worsening the symptoms or the participants have declined approved treatments. This research study, involves two experimental drugs called JTX-8064 (also known as “study drug”) and JTX-4014. JTX-8064 and JTX-4014 are investigational drugs.